From year to year, it is important to get an overview of the occurrence of causative agents in febrile neutropenic patients to determine the empiric treatment. Thus our aims were to evaluate a four-year period regarding the prevalence of bloodstream infections and the most important causative agents. During this period, 1,361 patients were treated in our hematology ward because of various hematological disorders. 812 febrile episodes were recorded in 469 patients. At that time, 3,714 blood culture (BC) bottles were sent for microbiological investigations, 759 of them gave positive signal. From the majority of positive blood culture bottles (67.1%), Gram-positive bacteria, mainly coagulase-negative staphylococci (CNS), were grown. Gram-negative bacteria were isolated from 32.9% of the positive blood culture bottles, in these cases the leading pathogen was Escherichia coli. The high prevalence of CNS was attributed to mainly contamination, while lower positivity rate for Gram-negative bacteria was associated with the use of broad-spectrum empiric antibiotic treatment.
Crawford J , Dale DC, Lyman GH: Chemotherapy-induced neutropenia: risks, consequences, and new direction for its management. Cancer 100, 228–237 (2004)
Madani TA : Clinical infections and bloodstream isolates associated with fever in patients undergoing chemotherapy for acute myeloid leukemia. Infection 28, 367–373 (2000)
Peters RPH , van Agtmael MA, Danner SA, Savelkoul PHM, Vandenbroucke-Grauls CMJE: New developments in the diagnosis of bloodstream infections. Lancet Infect Dis 4, 751–760 (2004)
Schimpff S , Satterlee W, Young VM et al.: Emipiric therapy with carbenicliin and gentamicin for febrile patients with cancer an granulocytopenia. N Engl J Med 284, 1061–1065 (1971)
Baden LR : Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 353, 1052–1054 (2005)
Hammond SP , Baden LR: Antibiotic prophylaxis for patients with acute leukemia. Leuk Lymphoma 49, 183–193 (2008)
Hughes WT , Armstrong D, Bodey GP et al.: Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Inf Dis. 34, 730–751 (2002)
Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Fifteenth Informational Supplement. CLSI document M100-S15 (ISBN 1-56238-556-9)
Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement. CLSI document M100-S16 (ISBN 1-56238-588-7)
Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement. CLSI document M100-S17 (ISBN 1-56238-625-5)
Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement. CLSI document M100-S18 (ISBN 1-56238-653-0)
Mermel LA , Allon M, Bouza E et al.: Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 49, 1–45 (2009)
Keng MK , Sekeres MA: Febrile neutropenia in hematologic malignancies. Curr Hematol Malig Rep 8, 370–378 (2013)
Bodey GP . Buckley M, Sathe YS, Freireich EY: Quantitative relationship between circulating leukocytes and infections in patients with acute leukemia. Ann Intern Med 64, 328–340 (1966)
Syrjala H , Ohtonen P, Kinnunen U, Raty R, Elonen E, Nousiainen T, Jantunen E, Remes K, Itala-Remes M, Silvennoinen R, Koistinen P, Finnish Leukemia Group: Bloodstream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters. Eur J Clin Microbiol Infect Dis 29, 1211–1218 (2010)
Ramphal R : Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 39, 25–31 (2004)
Klastersky J , Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Paesamns M: Bacteremia in febrile neutropenic cancer patients. Int J Antimicrob Ag 30S, S51–S59 (2007)
Viscoli C , Cometta A, Kern WV et al.: Piperacillin–tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect 12, 212–216 (2006)
Winston DJ , Lazarus HM, Beveridge RA et al.: Randomized, double-blind, multicentre trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis 32, 381–390 (2001)
DelFavero A , Menichetti F, Martino P et al.: A multicentre, double-bind, placebo-controlled trial comparing piperacillin–tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 33, 1295–1301 (2001)
Cordonnier C , Buzyn A, Leverger G et al.: Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 36, 149–158 (2003)
Picazo JJ : Management of the febrile neutropenic patient: a consensus conference. Clin Infect Dis 39, 1–6 (2004)